EMBO Member
Cleveland Clinic Foundation | United States
EMBO 1985 | Council 90–91 | EefC 91–92
We study signal transduction pathways that affect STAT and NFkB activation and function, especially novel lysine methylations and serine/threonine phosphorylations. We also study the novel effect of interferon-induced oligoadenylate synthetases on polyADPribose structure and function, and on DNA repair. Finally, we study the mechanisms of the antitumor drug CBL137 in preferentially killing cancer stem cells and in synergizing with DNA damaging therapies in cancer.
Keywords: Interferons / cancer stem cells / NF-kappaB / STATs / DNA repair
Subject area(s): Chromatin & Transcription | Molecular Medicine | Signal Transduction